28 results for Patent, 2000

  • Transcription Factors

    Bloksberg, LN; Bryant, C; Connett, MB; Emerson, SJ; Frost, MJ; Forster, RLS; Grigor, M; Higgins, C; Lasham, Annette; Lund, ST; Magusin, A; Phillips, J; Puthigae, S; Veerakone, S; Westwood, C; Gause, K; Wood, M; Havukkala, I; Rottmann, WH (2009-03-24)

    Patent
    The University of Auckland Library

    View record details
  • Murine endometriosis modelled by K-ras activation of menstruating endometrium

    Charnock-Jones, D; Print, Cristin; Cheng, C (2009)

    Patent
    The University of Auckland Library

    View record details
  • 5-Substituted-4-[(substituted phenyl)amino]-2-pyridone derivatives

    Black, Shannon; Kaufman, MD; Ortwine, DF; Plummer, MS; Quin, J; Rewcastle, Gordon; Shahripour, AB; Spicer, Julie; Whitehead, CE (2007)

    Patent
    The University of Auckland Library

    The present invention relates to 5-substituted-4-(substituted)phenylamino-2-pyridone derivatives, pharmaceutical compositions and methods of use thereof.

    View record details
  • Effects of Glycyl-2-methylprolylglutamate on Neurodegeneration

    Gluckman, Peter; Thomas, GB; Guan, J; Dragunow, M; Anand, Ashmit; Kerlero de Rosbo, N; Sieg, F; Brimble, Margaret (2007-12-27)

    Patent
    The University of Auckland Library

    This invention provides analogs and peptidomimetics of glycyl-L-prolyl-L-glutamic acid (GPE). In particular, this invention relates to GPE analogs and peptidomimetics that are anti-apoptotic, anti-necrotic and have neuroprotective effects. These agents are useful in treating neurodegeneration and behavioural disorders caused by toxins, traumatic brain injury and autoimmune disorders of the brain, such as multiple sclerosis and in reducing seizures.

    View record details
  • Neuroprotective Bicyclic Compounds and Methods for their Use

    Brimble, Margaret; Guan, Jian; Sieg, Frank (2005-03-17)

    Patent
    The University of Auckland Library

    Embodiments of this invention provide novel cyclic compounds structurally related to diketopiperazines and methods for their therapeutic use. Such compounds are neuroprotective and have utility as therapeutic agents for treatment of diseases, injuries and other conditions characterised by neuronal degeneration and/or death. Compounds are also useful for manufacture of medicaments useful for treatment of such conditions.

    View record details
  • Pyrazolo[1,5-a]pyridines and their use in cancer therapy

    Kendall, JD; Marshall, Andrew (2009)

    Patent
    The University of Auckland Library

    Phosphoinositide-3-kinases (PI3Ks) are a group of lipid kinases which phosphorylate the 10 3-hydroxyl of phosphoinositides. They are split into three classes (Class I, II and Ill) and play an important role in cellular signalling [Stephens et al., Curr. Opin. Pharmacal. 2005, 5, 357]. The Class I enzymes are further split into Class Ia and lb based on their mechanism of activation; the Class Ia PI3Ks are heterodimeric structures consisting of a catalytic subunit (p11 Oa, p11 013 or p11 0~) in complex with a regulatory p85 subunit, while 15 the class-IB PI3K (p11 Oy) is structurally similar but lacks a reguiatory subunit linking and instead is activated by 13v subunits of heterotrimeric G-proteins [Walker et al,. Moi.Ce/1., 2000, 6, 909]. PI3Ks play a variety of roles in normal tissue physiology [Foukas & Shepherd, Biochem. 20 Soc. Trans., 2004,32, 330; Shepherd,Acta Physiol. Scand,. 2005, 183, 3], with p110a having a specific role in cancer growth, p11 013 in thrombus formation mediated by integrin aul33 [Jackson et al., Nat. Med., 2005, 11, 507], and p11 Oy in inflammation, rheumatoid arthritis [Camps et al., Nat. Med., 2005, 11, 936] and other chronic inflammation states [Barber et al., Nat. Med., 2005, 11, 933]. The PI3K enzymes produce phosphoinositide 25 3,4,5-triphosphate (PIP3) from the corresponding diphosphate (PIP2), thus recruiting AKT (protein kinase B) through its PH domain, to the plasma membrane. Once bound, AKT is phosphorylated and activated by other membrane bound kinases, and is central to a cascade of events that lead to inhibition of apoptosis [Berrie, Exp. Opin. Invest. Drugs, 2001, 10, 1085].

    View record details
  • Microscopic dynamic mechanical analyzer

    Garcia-Webb, MW; Hunter, IW; Taberner, Andrew (2009)

    Patent
    The University of Auckland Library

    An electromagnetic apparatus, comprises a conductive loop comprising two parallel conductive legs joined at a free end by a sample contacting member and a magnetic circuit that imposes a magnetic field in opposite directions across the respective legs. A method of mechanically characterizing a sample, comprises imposing a magnetic field in opposite directions in each of two parallel conductive legs of a conductive loop, the legs joined at a free end by a sample contacting member.

    View record details
  • Cascaded Raman Laser

    Martinelli, C; Leplingard, F; Sylvestre, T; Vanholsbeeck, Frederique; Emplit, P (2006-02-07)

    Patent
    The University of Auckland Library

    A cascaded Raman laser (10) has a pump radiation source (12) emitting at a pump wavelength λp, an input section (14) and an output section (16) made of an optical medium. Each section (14, 16) comprises wavelength selectors (141, 142, . . . , 145 and 161, 162, . . . , 165) for wavelengths λ1, λ2, . . . , λn−k, where n≧3, λp< . . . <λn and λn−k+1, λn−k+2, . . . , λn being k≧1 emitting wavelengths of the laser (10). The laser further comprises an intracavity section (18) that is made of a non-linear optical medium, has a zero-dispersion wavelength λ0 and is disposed between the input (14) and the output (16) section. The wavelengths λ1, λ2, . . . , λn−k of the wavelength selectors (141, 142, . . . , 145 and 161, 162, . . . , 165) and the zero-dispersion wavelength λ0 of the intracavity section (18) are chosen such that energy is transferred between different wavelengths by multi-wave mixing.

    View record details
  • Quinoline derivatives for modulating DNA methylation.

    Brooke, Darby; Phiasivongsa, P; Denny, WA; Gamage, S; Bearss, DJ; Vankayalapati, H; Redkar, SG (2009)

    Patent
    The University of Auckland Library

    (EN)Quinoline derivatives, particularly 4-anilinoquinoline derivatives, are provided. Such quinoline derivatives can be used for modulation of DNA methylation, such as effective inhibition of methylation of cytosine at the C-5 position, for example via selective inhibition of DNA methyltransferase DNMT1. Methods for synthesizing numerous 4-anilinoquinoline derivatives and for modulating DNA methylation are provided. Also provided are methods for formulating and administering these compounds or compositions to treat conditions such as cancer and hematological disorders. (FR)Cette invention concerne des dérivés de quinoline, en particulier des dérivés de 4-anilinoquinoline. Ces dérivés de quinoline peuvent être utilisés dans la modulation de la méthylation de l'ADN, par exemple dans l'inhibition effective de la méthylation de la cytosine en position C-5, par exemple par une inhibition sélective de l'ADN méthyltransférase DNMT1. L'invention concerne par ailleurs des procédés permettant de synthétiser plusieurs dérivés de 4-anilinoquinoline et de moduler la méthylation de l'ADN. L'invention concerne également des procédés permettant de formuler et d'administrer ces composés ou ces compositions pour traiter des pathologies comme le cancer et les troubles hématologiques.

    View record details
  • Needle-free transdermal transport device

    Ball, NB; Hemond, BD; Hogan, NC; Hunter, IW; Taberner, Andrew; Wendell, DM (2009-08-16)

    Patent
    The University of Auckland Library

    needle-free transdermal transport device for transferring a substance across a surface of a biological body includes a reservoir for storing the substance, a nozzle in fluid communication with the reservoir and a controllable electromagnetic actuator in communication with the reservoir. The actuator, referred to as a Lorentz force actuator, includes a stationary magnet assembly and a moving coil assembly. The coil assembly moves a piston having an end portion positioned within the reservoir. The actuator receives an electrical input and generates in response a corresponding force acting on the piston and causing a needle-free transfer of the substance between the reservoir and the biological body. The magnitude, direction and duration of the force are dynamically controlled (e.g., servo-controlled) by the electrical input and can be altered during the course of an actuation cycle. Beneficially, the actuator can be moved in different directions according to the electrical input.

    View record details
  • Diagnostically and audibly responsive computer learning memory game and system provided therefor

    Dowrick, Peter (2006)

    Patent
    The University of Auckland Library

    A diagnostically and audibly responsive computer learning memory game works with small children and other persons in teaching them to read. Square or rectangular tiles to be uncovered are displayed upside down, concealing words to be matched with words or words to be matched with phrases or visual pictures or audible sounds, objective is to find matching cards. The computer game matches the cards or tiles with sight words that the user is learning to read from a word list. The user must remember where a correct word of the word pairs is located. The user must read word orally, if not, the computer will prompt the user with a clue (such as the beginning sound of a word) until the user answers. If nothing is heard, the user is told the answer. The system has a built-in recording of a library of selected words, phrases, pictures or audible sounds. The computer can sense that user is silent (with a default of no sound). If a wrong word is uttered, the system can remain silent or correct..

    View record details
  • Polypeptides and Polynucleotides for Artemin and related Ligands, and Methods of Use Thereof

    Liu, Dongxu; Lobie, Peter (2008)

    Patent
    The University of Auckland Library

    The invention encompasses polypeptides, polynucleotides, and antibodies, for Artemin and related ligands, including Persephin (PSPN). The invention also encompasses expression vectors and host cells for producing these polypeptides, polynucleotides, or antibodies. The invention further encompasses diagnostics and therapeutics, especially for cancer, and particularly breast cancer, colon cancer, prostate cancer, endometrial cancer, lung cancer, stomach cancer, liver cancer, and others, comprising one or more of the disclosed polypeptides, polynucleotides, antibodies, expression vectors, host cells, or compositions thereof. Particularly encompassed are inhibitors of Artemin and/or related ligands, and uses for these inhibitors.

    View record details
  • Novel Saratan Polypeptides and Polynucleotides and Methods of Use Thereof

    Liu, Dongxu; Lobie, Peter (2008)

    Patent
    The University of Auckland Library

    The invention relates to Saratan polypeptides, polynucleotides, and antibodies. The invention also relates to expression vectors and host cells for producing these polypeptides, polynucleotides, or antibodies. The invention further relates to diagnostics and therapeutics, especially for cancer, and particularly breast cancer, comprising one or more of the disclosed polypeptides, polynucleotides, antibodies, expression vectors, host cells, or compositions thereof.

    View record details
  • GPE Analogs and Peptidomimetics

    Abood, NA; Brimble, Margaret (2003-03-20)

    Patent
    The University of Auckland Library

    This invention relates to analogs and peptidomimetics of glycyl-L-prolyl-L-glutamic acid (GPE). In particular, this invention relates to GPE analogs and peptidomimetics that are anti-apoptotic and anti-necrotic, to methods of making them, to pharmaceutical compositions containing them, and to their use.

    View record details
  • Adrenocorticotropic hormone analogs and related methods

    Brennan, MB; Costa, Jessica; Dores, RM; Hochgeschwender, U; Haskell-Luevano, C (2007)

    Patent
    The University of Auckland Library

    ACTH analog compounds of the present invention include compounds comprising an ACTH peptide sequence with one or more structural modifications that can have one or more of the following preferred ACTH analog biological functions: (1) reduction of corticosteroid secretion by adrenal membrane in the presence of the ACTH analog compared to unmodified ACTH, (2) reduction of corticosteroid secretion by adrenal membrane in the presence of endogenous ACTH and (3) increased MC-2R binding affinity with reduced activation of the MC-2R receptor compared to unmodified ACTH binding to the MC-2R melanocortin. The ACTH analog compounds of the present invention are therefore useful for treatment or prevention of diseases and disorders related to ACTH, ACTH receptors or corticosteroid secretion, such as premature labor and Cushing's Disease.

    View record details
  • System and method for tracking facial muscle and eye motion for computer graphics animation

    Sagar, Mark; Scott, R (2009)

    Patent
    The University of Auckland Library

    A motion tracking system enables faithful capture of subtle facial and eye motion using a surface electromyography (EMG) detection method to detect muscle movements and an electrooculogram (EOG) detection method to detect eye movements. An embodiment of the motion tracking animation system comprises a plurality of pairs of EOG electrodes adapted to be affixed to the skin surface of the performer at locations adjacent to the performer's eyes. The EOG data comprises electrical signals corresponding to eye movements of a performer during a performance. Programming instructions further provide processing of the EOG data and mapping of processed EOG data onto an animated character. As a result, the animated character will exhibit he same muscle and eye movements as the performer.

    View record details
  • Inductively Powered Mobile Sensor System

    Malpas, Simon; Hu, AP; Budgett, David (2004-09-16)

    Patent
    The University of Auckland Library

    The present invention provides an inductively powered sensor system having a primary conductive path capable of being energized to provide an electromagnetic field in a defined space. An inductive power pick-up is associated with a sensor and is capable of receiving power from the field to supply the sensor. The system includes a first sensing unit to sense the power available to the pick-up and a control unit to increase or decrease the power available to the sensor dependant on the sensed power available. A method of inductively powering a sensor, an inductively powered sensor and an animal enclosure including one or more primary conductive path of an inductive power supply are also disclosed.

    View record details
  • Compositions and Methods for Regulating Plant Gene Expression

    Espley,, RV; Hellens,, RP; Allan,, AC; Chagn??,, D (2008)

    Patent
    The University of Auckland Library

    The invention provides a method for producing a chimeric promoter polynucleotide capable of controlling transcription of an operably linked polynucleotide in a plant cell or plant, wherein the method comprises combining: a) at least one sequence motif comprising a sequence with at least 70% identity to SEQ ID NO:1, 11 or 12, and b) another polynucleotide sequence. The invention also provides chimeric promoters polynucleotides comprising the sequences defined in a) and b). The invention also provides constructs, vectors, host cells, plant cells and plants comprising the chimeric promoter polynucleotides of the invention. The invention also provided methods for modifying gene expression and phenotype of plant cells and plants by transforming the plant cells and plants with the chimeric promoter polynucleotides of the invention.

    View record details
  • Cell marker of melanocyte cell lineage and uses thereof

    Dunbar, PR; Horlacher, O; Feisst, Vaughan (2009)

    Patent
    The University of Auckland Library

    The present invention relates to a novel protein that is a marker of melanocyte cell lineage and cancer cells, and to nucleic acids encoding the novel protein. The invention also relates to treatment of disorders of cells of the melanocyte lineage, and to compositions and methods for treatment of such disorders.

    View record details
  • Oral formulations of Glycyl-2-Methylprolyl-Glutamate.

    Wen, Jingyuan; Thomas, G; Bickerdike, MJ (2009)

    Patent
    The University of Auckland Library

    Oral formulations of G-2MePE including microemulsions, coarse emulsions, liquid crystals, tablets and encapsulated forms of G-2MePE have improved bioavailability than conventional aqueous formulations. In particular, microparticles, nanoparticles and microemulsions can exhibit great neuroprotective effects after oral administration. In a microemulsion formulation, G-2MePE can nearly completely inhibit cerebral infarction in an animal model of stroke even after the stroke had been initiated. Thus, improved oral formulations can be desirably used to treat a variety of neurodegenerative conditions with improved convenience and improved efficacy.

    View record details